Advocacy intelligence hub — real-time data for patient organizations
NETSPOT: FDA approved
For use after radiolabeling with Ga 68, with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
NETSPOT
Advanced Accelerator Applications, USA
NETSPOT
(Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide)Orphan drugAdvanced Accelerator Applications, USA
12.1 Mechanism of Action Gallium Ga 68 dotatate binds to somatostatin receptors, with highest affinity for subtype 2 receptors (SSTR2). It binds to ce...
Shivaani Kummar, MD
NCI - Medical Oncology Branch
📍 PORTLAND, OR
Scot C. Remick, MD, MD
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
📍 SCARBOROUGH, ME
View all Classic neuroendocrine tumor of appendix specialists →